Lipella Pharmaceuticals Earnings Call Transcripts

Fiscal Year 2025

Life Sciences Virtual Investor Forum 2025

Proprietary liposomal technology enables targeted delivery for mucosal diseases, with LP-10 oral rinse showing strong safety and efficacy in phase two OLP trials. Addressing a significant unmet need, LP-10 targets a $750M peak sales opportunity, with next steps including a placebo-controlled trial and industry partnership.

Read full transcript →